Literature DB >> 29581353

Optical coherence tomography angiography in comparison with other multimodal imaging techniques in punctate inner choroidopathy.

Dominika Pohlmann1, Uwe Pleyer1, Antonia M Joussen1, Sibylle Winterhalter1.   

Abstract

AIMS: To characterise punctate lesions and choroidal neovascularisation (CNV) in eyes with punctate inner choroidopathy (PIC) using current standard multimodal imaging techniques and optical coherence tomography angiography (OCTA).
METHODS: In our prospective, single-centre study, 20 individuals with PIC underwent imaging with spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), indocyanine green angiography, fundus autofluorescence, fundus colour photography and OCTA.
RESULTS: Thirty-two eyes of 20 patients were affected. Eight (20%) eyes revealed typical punctate lesions, while 24 (60%) eyes had confirmed CNV on SD-OCT and FA in addition to punctate lesions. Of these 24 eyes with CNV, a reoccurrence of active CNV was detected in 5 (21%) eyes, a residual fluid in 3 (13%) eyes, while 16 (67%) eyes were defined as being stable. On OCTA, CNV was classified as having 'lacy wheel', 'pruned large-trunk' and 'dead tree aspect' vessel shapes with or without areas of non-perfusion. The disease activity was dependent on several predictors in the regression analysis such as intraretinal fluid (p=0.0014), CNV type (p=0.0199), leakage (p<0.0001) and hypoperfusion/non-perfusion (p<0.0001) on OCTA.
CONCLUSION: OCTA offers additional valuable insight into the current standard multimodal imaging techniques used for characterisation of PIC. This imaging technique can be a useful tool for analysis of disease activity. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  imaging; immunology; macula; retina

Mesh:

Year:  2018        PMID: 29581353     DOI: 10.1136/bjophthalmol-2017-311764

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  6 in total

1.  [White dot syndromes : Principles, diagnostics, and treatment].

Authors:  Dominika Pohlmann; Sibylle Winterhalter; Uwe Pleyer
Journal:  Ophthalmologe       Date:  2019-12       Impact factor: 1.059

2.  Intra and inter-rater agreement of inflammatory choroidal neovascular membrane measurements using optical coherence tomography angiography.

Authors:  Inês Leal; Shi Zhuan Tan; Tariq Aslam; Laura R Steeples; Nicholas P Jones; Ramandeep Chhabra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-19       Impact factor: 3.117

3.  Swept Source-Optical Coherence Tomography Angiography for Management of Secondary Choroidal Neovascularization in Punctate Inner Choroidopathy.

Authors:  Martin Stattin; Julia Forster; Daniel Ahmed; Katharina Krepler; Siamak Ansari-Shahrezaei
Journal:  Case Rep Ophthalmol       Date:  2021-04-12

4.  Optical Coherence Tomography Findings of Underlying Choroidal Neovascularization in Punctate Inner Choroidopathy.

Authors:  Aniruddha Agarwal; Sabia Handa; Alessandro Marchese; Salvatore Parrulli; Alessandro Invernizzi; Roel J Erckens; Tos T J M Berendschot; C A B Webers; Reema Bansal; Vishali Gupta
Journal:  Front Med (Lausanne)       Date:  2021-12-22

5.  The use of optical coherence tomography angiography in comparing choriocapillaris recovery between two treatment strategies for multifocal choroiditis: a pilot clinical trial.

Authors:  Aniruddha Agarwal; Khushdeep Abhaypal; Kanika Aggarwal; Roel J Erckens; Tos T J M Berendschot; C A B Webers; Mohit Dogra; Reema Bansal; Vishali Gupta
Journal:  J Ophthalmic Inflamm Infect       Date:  2022-03-11

6.  Spectral domain-optical coherence tomography retinal biomarkers in choroidal neovascularization of multifocal choroiditis, myopic choroidal neovascularization, and idiopathic choroidal neovascularization.

Authors:  Rui Gao; Jingxue Ma; Zhengwei Zhang; Qingli Shang; Jialiang Duan
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.